Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels, resulting in vision loss and blindness, if left untreated. DME…
Sarcoidosis is a rare inflammatory disease that causes the formation of granulomas—small lumps or nodules. Although it primarily affects the lungs, it can involve multiple organs, including the…
Dry eye disease (DED) is a condition characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. For 13 years, AbbVie’s Restasis was…
The wet age-related macular degeneration (AMD) market in the United States is replete with intravitreal (IVT) therapies—including Regeneron’s Eylea, Roche / Genentech’s Lucentis and Vabysmo,…
Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels, resulting in vision loss and blindness, if left untreated. DME…
Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), is a leading cause of visual impairment and blindness in the United States and Europe. Degradation of cells…
Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), is a leading cause of visual impairment and blindness in the United States and Europe. Degradation of cells…
Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands; the disease may occur alone (primary SS) or…
Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands; the disease may occur alone (primary SS) or…
For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…
For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…
Most uveitis-related vision loss is the result of chronic inflammation of the posterior segment of the eye. Although noninfectious anterior uveitis is typically treated successfully with topical…
Most uveitis-related vision loss is the result of chronic inflammation of the posterior segment of the eye. Although noninfectious anterior uveitis is typically treated successfully with topical…
Epidemiology Data Slicer